title: Pembrolizumab induced bulbar myopathy and respiratory failure with necrotizing myositis of the diaphragm.
authors.affiliation: Departments of Medical Oncology, Mayo Clinic, Rochester, MN, USA.
authors.forename: C L
authors.initials: CL
authors.lastname: Haddox
authors.affiliation: Departments of Medical Oncology, Mayo Clinic, Rochester, MN, USA.
authors.forename: N
authors.initials: N
authors.lastname: Shenoy
authors.affiliation: Anatomic/Clinical Pathology, Mayo Clinic, Rochester, MN, USA.
authors.forename: K K
authors.initials: KK
authors.lastname: Shah
authors.affiliation: Neurology , Mayo Clinic, Rochester, MN, USA.
authors.forename: J C
authors.initials: JC
authors.lastname: Kao
authors.affiliation: Departments of Medical Oncology, Mayo Clinic, Rochester, MN, USA.
authors.forename: S
authors.initials: S
authors.lastname: Jain
authors.affiliation: Departments of Medical Oncology, Mayo Clinic, Rochester, MN, USA.
authors.forename: T R
authors.initials: TR
authors.lastname: Halfdanarson
authors.affiliation: Anatomic/Clinical Pathology, Mayo Clinic, Rochester, MN, USA.
authors.forename: E F
authors.initials: EF
authors.lastname: Wijdicks
authors.affiliation: Departments of Medical Oncology, Mayo Clinic, Rochester, MN, USA.
authors.forename: M P
authors.initials: MP
authors.lastname: Goetz
mesh_terms: D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects* / Q000627:therapeutic use; D000074322:Antineoplastic Agents, Immunological / Q000009:adverse effects* / Q000627:therapeutic use; D003964:Diaphragm / Q000187:drug effects* / Q000473:pathology*; D006801:Humans; D008297:Male; D008545:Melanoma / Q000188:drug therapy; D009220:Myositis / Q000139:chemically induced* / Q000473:pathology; D012131:Respiratory Insufficiency / Q000139:chemically induced* / Q000473:pathology
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000074322:Antineoplastic Agents, Immunological; C582435:pembrolizumab